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SUMMARY
Microperforate hymens are rare anatomical variants with
an unknown incidence and very few reported cases.
Borderline ovarian tumours are similarly uncommon, with
an incidence of approximately 0.002%–0.006%. The
concurrent presence of a microperforate hymen and a
borderline ovarian tumour is therefore exceedingly unique
with no documented cases to date. In this report, we
review the case of a nulliparous woman in her late 20s
who initially presented with an inability to have penetrative
intercourse. A subocclusive hymenal variant was noted on
examination and further imaging work-up resulted in the
incidental discovery of a large ovarian mass subsequently
noted to be a borderline ovarian tumour. Herein, we
review contemporary approaches to the diagnosis and
management of both hymenal variants and borderline
ovarian tumours, and discuss fertility-sparing strategies for
young women diagnosed with ovarian neoplasms.

to have penetrative vaginal intercourse. She
reported coitarche 2 months prior to presentation.
The patient and her partner attempted but never
achieved penetrative intercourse on two occasions;
both times, intercourse was suspended due to severe
dyspareunia. She experienced sexual arousal and
endorsed a desire to have penetrative intercourse
on both occasions. She reported regular menstrual
cycles and denied dysmenorrhoea, menorrhagia
or intermenstrual spotting. She attempted tampon
insertion once a few years prior to presentation, but
was unable to do so secondary to pain. Her gynaecological, medical, surgical, familial and social histories were otherwise unremarkable. The abdominal
examination revealed no masses or distention. On
pelvic examination, an intact vaginal hymen was
noted with two small perforations located just
beneath the urethra. Neither a digital nor speculum
examination could be performed.

BACKGROUND

INVESTIGATIONS

Microperforate hymens are exceptionally rare,
partially occlusive hymenal variants with an
unknown incidence rate.1–3 Although there is a
paucity of literature available on microperforate
hymens, documented cases were typically diagnosed in adolescent patients seeking evaluation for
symptoms such as primary amenorrhoea, atypical
menstrual bleeding (characterised by filiform or
watery-
appearing menses), prolonged spotting,
bleeding ‘from only one side of the vagina’, cyclic
abdominal pain, difficulty with tampon insertion,
recurrent vulvovaginitis, and changes in urinary and
bowel habits.1 4 5 When a microperforate hymen is
suspected, imaging with translabial or transperineal
ultrasound can help to differentiate these variants
from other anomalies, such as transverse vaginal
septa, Mayer-Rokitansky-Küster-Hauser syndrome
and vaginal agenesis.6
As subocclusive hymenal variants can lead to the
partial or complete obstruction of menstrual efflux,
it is not uncommon for patients to develop haematocolpos, haematometrocolpos or haematosalpinx.7 8 In fact, all reported cases of pelvic masses
in patients with known hymenal variants were
found to be benign accumulations of blood.9 To
our knowledge, this is the first report of an ovarian
neoplasm—ultimately identified as a borderline
serous ovarian tumour—discovered in a patient
undergoing evaluation of symptoms related to a
microperforate hymen.

CASE PRESENTATION

A nulliparous woman in her late 20s presented
to an outpatient gynaecologist with an inability

Translabial ultrasound was ordered to better typify
the patient’s hymenal variant and screen for any
additional genital anomalies. The ultrasound
revealed a large, vascularised presacral mass of
uncertain origin extending into the right adnexa
(figure 1). MRI was obtained for further characterisation that redemonstrated the 11.7×9.1×8.3
cm pelvic mass likely arising from the right ovary/
adnexal region with features favouring ovarian
neoplasm (figure 2).
Gynaecological oncology was consulted and
recommended CT scan of the chest, abdomen and
pelvis, as well as tumour markers. Tumour markers
were significant for an elevated cancer antigen 19-9
of 257.1 and cancer antigen 125 of 4233 (table 1). A
CT scan showed a non-enlarged uterus with a large,
heterogeneous-appearing pelvic mass 11.7×9.7 cm
in size. No additional masses or enlarged lymph
nodes were visualised (figure 3).

DIFFERENTIAL DIAGNOSIS

Following the completion of these diagnostic
studies, the patient met with a gynaecological
oncologist and was counselled that the differential
diagnosis of her pelvic mass included both benign
and malignant aetiologies.

TREATMENT

Given the patient’s strong desire for future fertility,
a plan was made to proceed with a stepwise, diagnostic approach starting with laparoscopy with
intra-
abdominal/ peritoneal biopsies and concurrent hymenectomy. Pending pathology results,
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Table 1

The patient’s tumour marker values and reference ranges

Tumour marker

Value

Normal reference range

Inhibin A (pg/mL)

13

<98

Inhibin B (pg/mL)

14

<153

CA 19-9 (U/mL)

257.1*

<45.1

CA 125 (U/mL)

4233*

<49

CEA (ng/mL)

0.7

<6.1

bHCG (mIU/mL)

<10

<10

LDH (IU/L)

180

<250

AFP (ng/mL)

1.8

<8.1

*abnormal
AFP, alpha-fetoprotein; bHCG, beta-human chorionic gonadotropin; CA, cancer antigen;
CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase.

Figure 1 Translabial ultrasound image demonstrating a large pelvic
mass, measuring 10.4×8.9×9.3 cm.
final recommendation for surveillance versus definitive surgical
management would be offered. Two weeks later, the patient
underwent the above-
listed procedures. Examination under
anaesthesia was consistent with a microperforate hymen, and an
uncomplicated hymenectomy was performed (figure 4). Upon
abdominal entry with the laparoscope, a large mass seemingly
originating from the right ovary with fatty-appearing papillary-
like projections that extended to the posterior cul-de-sac was
observed (figure 5). The uterus, left ovary, left fallopian tube,
omentum, bowel, liver and abdominal wall appeared grossly
normal. The papillary-
like projections extending from the
ovarian lesion were biopsied using bipolar energy, and care was
taken to ensure that the mass remained intact. Omental biopsies
and some of the free fluid noted in the pelvis were also collected.
All surgical specimens were sent to pathology for evaluation.
Although frozen pathology was initially concerning for ‘adenocarcinoma’, the final pathology report suggested ‘at least serous
borderline tumour, invasive disease cannot be excluded’.
Given the patient’s young age and strong desire for future
fertility, she was counselled on the option of either radical or
conservative fertility-
sparing surgical management. Following
extensive discussion about the risks and benefits of both
approaches, she elected for the fertility-
sparing strategy and
underwent consultation with both reproductive endocrinology
and infertility and colorectal surgery specialists. She was counselled on, but ultimately declined, embryo cryopreservation. Five
weeks after her initial diagnostic laparoscopy and hymenectomy,

Figure 2 MRI demonstrating an 11.7×9.1×8.3 cm pelvic mass,
assumed to be arising from the right ovary/adnexa.
2

she was boarded for exploratory laparotomy. The gross appearance of the mass was stable from prior (figure 6) and the lesion
was noted to be adhered to the posterolateral aspect of the
uterus but not fixed within the pelvic cavity. Uncomplicated right
salpingo-oophorectomy was performed, resulting in complete
resection of the pelvic mass, as well as peritoneal biopsies,
infragastric omentectomy and right pelvic lymph node dissection. Frozen pathology was consistent with ‘at least borderline
tumour’, which prompted our staging biopsies and pelvic lymph
node biopsies. Final pathology demonstrated ‘serous borderline
tumour of the ovary with negative peritoneal and lymph node
biopsies’.

OUTCOME AND FOLLOW-UP

Given her final diagnosis of stage 1C3 serous borderline tumour
of the ovary, recommendation for surveillance was made and the
patient was scheduled for a 6-month follow-up with gynaecological oncology.

DISCUSSION

The presented case represents the confluence of two particularly rare gynaecological anomalies: (1) a subocclusive hymenal
variant and (2) an incidentally discovered borderline ovarian
tumour (BOT).
The vaginal hymen is formed by the invagination of the posterior wall of the urogenital sinus and typically ruptures during the
perinatal period, resulting in a thin mucous membrane remnant
within the vaginal orifice.10 Incomplete dissolution of the hymen
can result in a number of hymenal variants, including microperforate hymens. Unlike patients with completely imperforate hymens who classically present during puberty with cyclic
abdominal pain and dark-coloured or blue-tinged vaginal bulges,
patients with subocclusive hymenal variants may have normal
or partial menstrual efflux.11 Therefore, the initial diagnosis of
these variants may occur later in adolescence or even adulthood

Figure 3 CT imaging showing a non-enlarged uterus with a large,
heterogeneous-appearing pelvic mass.
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Figure 4 Microperforate hymen with two small microperforations
located just inferior to the urethra (A). Vaginal introitus status after
uncomplicated hymenectomy (B).
when patients present because they have difficulty placing or
removing tampons or are unable to have penetrative vaginal
intercourse.1 11 When a hymenal variant is suspected, the physical examination plays a critical role in characterising the specific
variant. Furthermore, imaging via translabial/transperineal ultrasound or MRI may aid in the differentiation of imperforate or
subocclusive hymens from other anatomical anomalies such as
labial adhesions, transverse or longitudinal vaginal septa, distal
vaginal atresia, cervical atresia and obstructed uterine horns.11
Ultimately, surgery is required for the definitive management
of an imperforate or subocclusive hymenal variant. Hymenectomy allows for complete efflux of menses and reduces patients’
risk for the accumulation of menstrual fluid and subsequent
distension of the vagina, uterus or fallopian tubes. Hymenectomy may also resolve other symptoms associated with hymenal
variants, including recurrent vulvovaginitis, dysmenorrhoea,
urinary retention, dysuria, constipation and dyschezia. Patients
should be counselled that those with isolated hymenal variants
who undergo hymenectomy are not at increased risk of infertility,
long-term sexual dysfunction or adverse obstetic outcomes. It is
recommended that hymenectomy be carried out with an initial
cruciate incision using either sharp or cautery dissection with
care taken to avoid damage to the urethra. Following excision
of the redundant hymenal tissue, the mucosal edges should be
re-approximated using a 3-0 or 4-0 absorbable suture in an interrupted fashion, and the vagina should be copiously irrigated.11
Patients typically do not require dilator use, pelvic floor physical therapy or topical oestrogen after hymenectomy; however,
these interventions may be considered if there is postoperative
concern for adhesions or stenosis.
Approximately 15% of all primary ovarian neoplasms are
considered BOTs, possessing features that are intermediate to
those of benign and overtly malignant ovarian neoplasms of
similar cell types.12 Ovarian cancer encompasses multiple types
of cancers, including epithelial and non-epithelial cancers, and
small cell carcinomas and carcinosarcomas, which are histologically composed of both an epithelial and a sarcomatous

Figure 5 Diagnostic laparoscopy revealed pelvic mass seemingly
originating from the right ovary with fatty-appearing papillary-like
projections, fixed to the posterior cul-de-sac.
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Figure 6 Complete excision of right fallopian tube, ovary and
associated mass.
component.13 Serous BOTs are the most common and best
understood histological subtype, accounting for approximately
65% of all BOTs.14 The vast majority of serous BOTs are stage
I at the time of diagnosis, contributing to the overall excellent
prognosis of these tumours with 5-year and 10-year survival
rates of 99% and 97%, respectively.14–16 However, it has been
estimated that the 10-year survival rate for even advanced stage
(stage II or higher) BOTs is between 70% and 90%.17
As approximately one-
third of all BOTs are diagnosed in
patients younger than 40 years, the decision to proceed with a
complete staging procedure versus a more conservative surgical
approach may be significantly influenced by a patient’s desire for
future fertility.18 The fertility-sparing approach to the management of apparent unilateral serous BOTs involves either unilateral salpingo-
oophorectomy or ‘cystectomy’. Performance of
pelvic washings, omental biopsy and biopsy of any visible peritoneal lesions is recommended with either procedure.19 Fertility-
sparing surgery with or without platinum-based chemotherapy
remains the standard of care of non-epithelial ovarian cancers,
providing a high chance of cure at all stages.20 The majority of
young women who are treated with that strategy may expect
recovery of ovarian function, usually within a few months after
treatment.21 Fertility seems to be only marginally affected by
treatment, with many reports of successful pregnancies and over
85% have been shown to regain menstrual function once chemotherapy was completed.22 23 The efficacy of unilateral salpingo-
oophorectomy versus cystectomy is highly debated, and there are
mixed data on the rate of recurrence and subsequent fertility with
one approach over the other. A systematic review of more than
100 relevant publications determined that the pooled estimate
for spontaneous pregnancy rate following conservative surgical
management (either unilateral salpingo-oophorectomy or cystectomy) of an early stage BOT was approximately 54%. For this
same pooled cohort, the risk of lethal recurrence was low at an
estimated 0.5%.24 Patients who have undergone fertility-sparing
surgery with borderline disease confirmed by final pathology
are recommended to follow up with gynaecological oncology
every 3–6 months with physical/pelvic examination and cancer
antigen 125 (if initially elevated) at every visit for 5 years. Thereafter, annual visits are recommended with imaging as clinically
3
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indicated. For patients who have elected for a fertility-sparing
approach, the National Comprehensive Cancer Network presently recommends consideration of completion surgery—with
removal of the contralateral fallopian tube and ovary and/or
uterus—upon the conclusion of childbearing.25

Learning points
► A broad differential is always critical to consider in a woman

with suspected hymenal variant.

► When a hymenal variant is suspected, the physical

examination plays a critical role in characterising the specific
variant and follow-up imaging is significant to aid in the
differentiation of imperforate or subocclusive hymens from
other more involved anatomical anomalies.
► Young patients with ovarian mass would benefit from
a stepwise, diagnostic approach to allow for fertility
preservation opportunities during the diagnostic and
treatment process.
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